• Background IGV-001 is a personalized, autologous cancer cell-based immunotherapy conceived to deliver a tumor-derived antigenic payload in the context of immunostimulatory signals to patients with glioblastoma (GBM). (jefferson.edu)
  • It outlines current approaches employed at the preclinical and clinical trial interface towards reversing these processes in order to improve response to immunotherapy and survival outcomes for patients with cancer. (portlandpress.com)
  • Immunotherapy based on the adoptive transfer of ex vivo expanded and activated autologous tumor-reactive lymphocytes can mediate tumor regression in cancer patients. (unimedizin-mainz.de)
  • We successfully applied this strategy to the human TAAs p53, gp100 and MDM2-specific TCRs as promising antigens-driven immunotherapy for both melanoma and hematologic malignancies. (unimedizin-mainz.de)
  • PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) is an innovative way of combining the best features of two clinically proven cancer immunotherapy approaches, an oncolytic adenovirus and a peptide vaccine. (helsinki.fi)
  • Valo Therapeutics (Helsinki and Oxford) is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. (helsinki.fi)
  • The highly competitive Cancer Research Institute's Clinical Laboratory Integration Program (CRI CLIP) grant will support Verma's lab efforts to improve mitochondrial metabolism in immune cells to make immune checkpoint-based immunotherapy more effective in treating solid tumors. (umn.edu)
  • However, for now, immunotherapy has a limited efficacy rate of just 20% to 30% when treating patients with solid tumors. (umn.edu)
  • One of the primary challenges in using immunotherapy to treat solid tumors is that immune cells in solid tumors tend to have dysfunctional mitochondria. (umn.edu)
  • Immunotherapy constitutes an effective treatment for patients with certain types of cancer that have been resistant to chemotherapy and radiation treatment (e.g. melanoma). (edu.au)
  • Cancer vaccines exploiting the in vivo delivery of tumour specific (neo-)antigens to cross-presenting dendritic cells to improve the immunotherapy for melanoma, breast cancer, lymphoma, glioblastoma and virus-driven tumours. (edu.au)
  • Identify and validate new classes of tumour antigens that can constitute suitable targets for immunotherapy in various types of cancers. (edu.au)
  • For the last 10 years, immunotherapy has made a clinically significant impact on the treatment of several different types of cancer. (medscape.com)
  • Although promising, no immunotherapy drugs have been approved by the FDA to treat gastrointestinal malignancies outside of the recent approval of pembrolizumab for the treatment of patients with colon cancer with microsatellite instability (MSI). (medscape.com)
  • however, it is far from ideal because PD-L1-negative tumors may respond to immunotherapy and positive tumors may not. (medscape.com)
  • Other factors have been suggested to correlate with response to immunotherapy based on clinical and preclinical studies, including elevated type 1 helper T cell (Th1) tumoral gene signature, [ 11 ] and IFN-γ expression, possibly attributable to its ties to other proteins and cytokines within the tumor microenvironment. (medscape.com)
  • Finally, some are engineering chimeric antigen receptor (CAR) T-cell systems that attack solid tumors and overcome the harsh barriers of the tumor microenvironment (TME). (genengnews.com)
  • Chimeric antigen receptors (CARs) operably link T cell activation domains to the antigen recognition properties of an antibody, thereby redirecting T lymphocytes to cells expressing the antigen. (bmj.com)
  • Chimeric antigen receptors (CAR)-engineered T cells have demonstrated remarkable efficacy in patients with B-cell malignancies. (unimedizin-mainz.de)
  • There are many therapeutic avenues that are being tried in clinics against solid tumors that include immune checkpoint inhibitors, adoptive cell therapy and chimeric antigen receptor (CAR) cell therapies, which are all susceptible to failure owing to exhaustion in immune cells," said Dr. Verma. (umn.edu)
  • We describe in both mice and humans a previously unrecognized pathway for the activation of tumor antigen-specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs). (nih.gov)
  • ADI-270 has demonstrated a highly differentiated profile stemming from its unique engineering, including targeting via a CAR that incorporates CD27, addition of dominant negative TGF beta receptor armoring, complimentary innate anti-tumor activity of the gamma delta 1 T cells and tissue tropism to solid tumors. (businesswire.com)
  • ADI-270 is designed to home to solid tumors, with a highly specific targeting moiety for CD70 and an armoring technology of dominant negative TGF beta receptor to address immunosuppressive factors in the tumor microenvironment. (businesswire.com)
  • In 2009, we had a seminal moment when you published a manuscript in The New England Journal of Medicine describing PLA2R, phospholipase A2 receptor, as the antigen that was responsible for a majority of the cases of MN. (medscape.com)
  • IGV-001 consists of patient-derived GBM cells treated with an antisense oligodeoxynucleotide against insulin-like growth factor 1 receptor (IGF1R) and placed in proprietary biodiffusion chambers (BDCs). (jefferson.edu)
  • The technique works by detecting the annihilation of positrons that occur within living subjects after administration of a positron-emitting radiotracer that is targeted to a specific receptor, transporter, enzyme or antigen. (hopkinsmedicine.org)
  • The various tumor markers differ in their usefulness for screening, diagnosis, prognosis, assessing therapeutic response, and detecting recurrence. (medscape.com)
  • It exhibits potent antitumor activity by activating tumor-infiltrating CD8 + and CD4 + T cells and has a better therapeutic window relative to recombinant human IL-2. (genengnews.com)
  • The expectation is that developing this new platform provides a more streamlined approach that will increase the throughput of tumor-reactive TCR discovery and, ultimately, therapeutic development. (swimacrossamerica.org)
  • Application of anti-PD-1/PD-L1 antibodies as checkpoint inhibitors is rapidly becoming a promising therapeutic approach in treating tumors, and some of them have successfully been commercialized in the past few years [ 10 ]. (hindawi.com)
  • To search for possible modes of action of retinoids as novel therapeutic options, primary tumor cell cultures were treated in vitro with all-trans-RA (ATRA), 9cis-RA, fenretinide and combinations of retinoids and a histone deacetylase (HDAC) inhibitor. (uni-wuerzburg.de)
  • Upon mRNA intratumoral injections in the transplantable mouse cancer models CT26, MC38, and B16OVA, potent therapeutic effects were observed following repeated injections into the tumors. (unav.edu)
  • Immune checkpoint-inhibitor combinations are the best therapeutic option for advanced hepatocellular car-cinoma (HCC) patients, but improvements in efficacy are needed to improve response rates. (unav.edu)
  • Therapeutic response correlates with the mutational load of the patient tumors, suggesting that neoantigens contribute to tumor rejection. (unimedizin-mainz.de)
  • Valo Therapeutics Limited (Valo Tx), an immuno-oncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines, today announced it had received additional funding, triggered by positive pre-clinical data, to progress its PeptiCRAd platform into first-in-human clinical trials. (helsinki.fi)
  • Michael Stein , CEO of Valo Tx, commented, "With our latest funding from existing investors, of EUR1.1m, we've now raised a total of over EUR 10m, which will enable us to further validate our platform to develop antigen-coated oncolytic viruses as therapeutic vaccines. (helsinki.fi)
  • This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. (ucsf.edu)
  • Therefore, the establishment of a solid pipeline for the downstream selection of clinically relevant peptides and the subsequent creation of therapeutic cancer vaccines are of utmost importance. (elifesciences.org)
  • Here, we describe for the first time a streamlined pipeline for the generation of personalized cancer vaccines starting from the isolation and selection of the most immunogenic peptide candidates expressed on the tumor cells and ending in the generation of efficient therapeutic oncolytic cancer vaccines. (elifesciences.org)
  • Tumour neo-antigen-specific immune responses in oesophageal cancer long-term survivors: proof-of-concept for improved personalised therapeutic strategies. (edu.au)
  • B-cell lymphomas (BCLs) constitute a diverse set of tially identify new functional, diagnostic, and therapeutic tumors, both morphologically and clinically, that are mainly targets. (lu.se)
  • Moving beyond biopsy, I am interested in the use of imaging to select patients who are candidates for prostate cancer focal therapy. (stanford.edu)
  • Prostate-specific antigen (PSA) screening for prostate cancer remains controversial because it increases overdiagnosis and overtreatment of clinically insignificant tumors. (lu.se)
  • We found that, in men of European ancestry, using PGS-adjusted PSA would avoid up to 31% of negative prostate biopsies but also result in 12% fewer biopsies in patients with prostate cancer, mostly. (lu.se)
  • This calculator has been developed to predict whether a man undergoing radical prostatectomy as primary treatment for clinically localized prostate cancer will have a PSA recurrence of his prostate cancer. (prostatecalculator.org)
  • Approximately 40,000 men undergo radical prostatectomy for the treatment of clinically localized prostate cancer in USA every year. (prostatecalculator.org)
  • The striking observation from two phase I clinical trials, in patients with prostate cancer immunized with prostate-specific antigen mRNA-transfected DCs and patients with renal cancer immunized with autologous tumor RNA-transfected DCs, was that the majority of patients exhibited a vaccine-induced T-cell response. (nova.edu)
  • Therefore, the aim of this study was to evaluate the effects of common genetic variants among eight immunodeficiency pathway-related genes on disease recurrence in prostate cancer patients treated with radical prostatectomy. (biomedcentral.com)
  • Genetic and bioinformatic analyses on 19 haplotype-tagging single-nucleotide polymorphisms in eight immunodeficiency pathway-related genes were conducted in 458 patients with prostate cancer after receiving radical prostatectomy. (biomedcentral.com)
  • In the present study, we first conducted a genetic analysis to evaluate the effects of common variants among eight immunodeficiency pathway-related genes on disease recurrence in 458 patients with prostate cancer after receiving radical prostatectomy. (biomedcentral.com)
  • This study was designed to determine if P30 and TAM reduced prostate specific antigen (PSA) in patients with early prostate cancer recurrence. (uky.edu)
  • Further studies are warranted to determine if these measurements correlate to anti-tumor activity better than PSA in patients with prostate cancer treated with TAM or other agents capable of modulating TGF-β1 or IGF-1. (uky.edu)
  • Gerald L. Andriole Objective: To identify which patients with prostate cancer are at high risk for local or distant recurrence after radical prostatectomy. (karger.com)
  • Prostate cancer is one of the most significant causes of morbidity and mortality in male patients. (bjbms.org)
  • Many genetic defects are listed as diagnostic, prognostic, and clinically actionable markers in prostate cancer. (bjbms.org)
  • 5 ] Some of the harms of overdiagnosis may be mitigated by strategies, such as active surveillance in prostate cancer, that attempt to defer immediate treatment in favor of following patients for any signs of worsening prognosis. (cancer.gov)
  • The US NCCN guidelines recommend that all, or a high proportion of, patients with a personal history of breast, ovarian, endometrial, pancreatic, colorectal, and prostate cancer should undergo germline testing. (cdc.gov)
  • PSA testing not only helps identify men in whom a prostate biopsy would be appropriate but also assists in assessing the response to therapy, determining tumor progression, and, in its most controversial role, screening for prostate cancer. (medscape.com)
  • however, most urologists would testify that they see far fewer patients with advanced prostate cancer since the PSA era began. (medscape.com)
  • Urologists obtain PSA measurements for most of their male patients in the appropriate age group because they believe they have an obligation to detect any prostate cancer at the earliest possible stage of its development. (medscape.com)
  • Hopefully, SAMS will increase our knowledge on active surveillance for low-risk prostate cancer, so that more patients with aggressive cancer will receive curative treatment and fewer patients will receive un-necessary treatment for indolent tumours and thereby maintain their quality of life better. (cancercentrum.se)
  • Engineered antibodies such as single-chain Fv antibodies (sFvs) or bispecific antibodies have been used for targeting and therapy of CEA expressing tumors both in vitro and in vivo with promising results Regions of high CEA levels in the body can be detected with the monoclonal antibody arcitumomab. (wikipedia.org)
  • Meanwhile, sintilimab is a human immunoglobulin G4 (IgG4) monoclonal antibody that specifically binds to the programmed death-1 (PD-1) molecule on the surface of T-cells, consequently blocking the tumor immune tolerance-inducing PD-1/programmed death-ligand 1 (PD-L1) pathway, reactivating the antitumor activities of lymphocytes, and inhibiting tumors [ 9 ]. (hindawi.com)
  • The sections were stained with an antibody directed against the Ki-67 antigen. (thejcdp.com)
  • Earlier clinical studies reported a high sensitivity of pretargeted immunoscintigraphy using murine or chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with 111 In or 131 I in medullary thyroid carcinoma (MTC). (snmjournals.org)
  • We developed a novel and simple immunoprecipitation technology for identifying clinical sera containing antigen-specific antibodies and for generating quantitative antibody response profiles. (biomedcentral.com)
  • After mixing crude extracts, sera and protein A/G beads together and incubating, during which the Ruc-antigen fusion become immobilized on the A/G beads, antigen-specific antibody is quantitated by washing the beads and adding coelenterazine substrate and measuring light production. (biomedcentral.com)
  • Efforts to identify antibody responses to tumor antigens are motivated primarily by their diagnostic potential. (biomedcentral.com)
  • Histopathology of peripheral nerve and sympathetic ganglion from a patient with autonomic failure, oat-cell carcinoma of the lung, and positive anti-HU antibody titer. (medscape.com)
  • report a case of a patient with metastatic gastric cancer with a meaningful response to the anti-programmed death-ligand 1 (PD-L1) antibody avelumab. (medscape.com)
  • NSCLC known to have a known or likely oncogenic-driver mutation in the EGFR gene, as identified by site local testing or Sponsor central testing Liver disease Positive hepatitis B surface antigen test at screening Patients known to be positive for hepatitis C virus antibody HIV infection, patients are excluded if HIV is not adequately controlled (specific criteria apply). (who.int)
  • HIV infection can be diagnosed by antibody, nucleic acid (HIV RNA), or antigen (p24) testing. (msdmanuals.com)
  • A consistent increase in a tumor marker value, combined with lack of clinical improvement, may indicate treatment failure. (medscape.com)
  • Ovarian cancer, uterine cervical cancer, endometrial cancer, and trophoblastic neoplasms are gynecologic malignancies for which tumor markers are in clinical use. (medscape.com)
  • No tumor markers with high sensitivity and high specificity for endometrial cancer are known at present, although CA-125 is often used in clinical practice. (medscape.com)
  • SCC antigen is useful in the clinical management of advanced cervical cancer. (medscape.com)
  • However, the serum levels are raised in some types of cancer, which means that it can be used as a tumor marker in clinical tests. (wikipedia.org)
  • Clinical and translational medicine data for our lead asset ADI-001 in NHL has provided us with valuable insights, which has guided us as we initiated the EXPAND cohort in post CAR T LBCL and continue to enroll MCL patients to the clinical study. (businesswire.com)
  • Adicet continues to expect that it will provide a clinical update from the Phase 1 study in NHL patients in the second half of 2024. (businesswire.com)
  • Following medical school, Dr. Sonn completed a 6-year urology residency at Stanford where he developed particular interests in the clinical care of patients with urologic cancers and research in cancer imaging. (stanford.edu)
  • Since finishing his fellowship, Dr. Sonn has been at Stanford where he applies the skills he gained in residency and fellowship to provide high-quality clinical care to patients with urologic cancers. (stanford.edu)
  • Each patient was followed up for at least 30 months to compare the short-term clinical efficacy and survival rate between the two groups. (hindawi.com)
  • Clinical data of 97 patients initially diagnosed with lung lesions in our hospital from January 2018 to December 2019 were collected and divided into the lung cancer group and benign lesion group. (ijpsonline.com)
  • There were 52 patients diagnosed with stage I or II lung cancer by computed tomography and clinical diagnosis in the lung cancer group and 45 patients with benign lesions in the benign lesion group. (ijpsonline.com)
  • Serum carcinoembryonic antigen and cytokeratin 19 were abnormally highly expressed in non-Small cell lung cancer patients, which are useful for clinical diagnosing, treatment planning, efficacy monitoring, and prognosis evaluation. (ijpsonline.com)
  • Whether in the early diagnosis of tumor, in the monitoring of metastasis and recurrence or in the evaluation of efficacy and prognosis, tumor markers were very important clinical reference indicators[ 4 , 5 ]. (ijpsonline.com)
  • Compared with the clinical monitoring techniques of Computed tomography (CT), Positron emission tomography computed tomography (PET-CT), and specific biomarkers, the detection of serum tumor markers was more simple, rapid and less invasive and has important clinical application value[ 6 - 9 ]. (ijpsonline.com)
  • Results: The association of retinoid signaling and clinical parameters could be validated in a large independent tumor set, but its relevance in primary nephrectomy tumors from very young children may be different. (uni-wuerzburg.de)
  • Across the patient journey from initial detection, to treatment and then monitoring, there are several points where DNA methylation assays can inform clinical practice. (frontiersin.org)
  • This review describes the use of mRNA-encoded tumor antigens as a form of antigen loaded onto DCs, including our early experience from clinical trials in urological cancers. (nova.edu)
  • IGV-001 has previously been shown to be generally safe with promising clinical activity in newly diagnosed GBM patients. (jefferson.edu)
  • Tumour-specific expression of MHC-I and MHC-II has been associated with improved patient survival in most clinical studies. (portlandpress.com)
  • Our findings have clinical implications for the design of next generation immune-based therapies for patients with cancer. (biomedcentral.com)
  • How lymphodepletion augments ACT in these various clinical trials has been elucidated in clinically relevant mouse models of melanoma. (biomedcentral.com)
  • In early phase clinical trials for both acute and chronic myeloid leukemias, we have observed the induction of anti-tumor immunity and associated clinical responses following K562/GM-CSF vaccination (see preliminary data). (acgtfoundation.org)
  • 2. Conduct a clinical trial in MDS testing K562/GM-CSF vaccination integrated with the systemic agent(s) identified in aim 1 as being most active in combination with GM-CSF tumor vaccines (years 2 and 3). (acgtfoundation.org)
  • The goal of this study was to assess the clinical efficacy of DAB/IL2 in an expanded cohort of stage IV melanoma patients. (biomedcentral.com)
  • Although the study was not designed to assess clinical efficacy, we did observe the regression of melanoma metastases in 3 patients. (biomedcentral.com)
  • In order to better define the clinical activity of DAB/IL2 against melanoma and provide rationale for randomized multi-center trials, we now have expanded this initial exploratory trial to include a total of 60 stage IV melanoma patients and will present herein the objective response rates and results of survival analyses. (biomedcentral.com)
  • Indeed, depending on the stage, priority will be given to both support for physical comfort, emotional and moral patient and mainly clinical investigations and treatments to cure or decelerate the progression of the disease in conjunction with other therapies that are intended to prolong life such as chemotherapy & radiotherapy [4]. (symbiosisonlinepublishing.com)
  • Nevertheless, the clinical benefit provided by current immunotherapeutic approaches is still limited to 25-30% of treated cancer patients. (edu.au)
  • Thirty to forty percent develop recurrence of serum prostate specific antigen (PSA) in 5-10 years. (prostatecalculator.org)
  • Physicians and patients need guidance in estimating the risk for recurrence in an individual patient. (prostatecalculator.org)
  • These patients did not receive adjunct hormonal therapy or radiation treatment prior to developing PSA recurrence. (prostatecalculator.org)
  • Proportional hazards regression analysis was used to model recurrence as a function of age, race, baseline PSA, pathologic tumor stage, seminal vesicle involvement, margin status, Gleason score and perineural invasion in the final pathology. (prostatecalculator.org)
  • By entry of few routinely used parameters, the model correctly identified 76% of the patients who developed a recurrence in the validation set. (prostatecalculator.org)
  • Previosu studies have indicated that tumor recurrence is common in HPC patients and thus, radiotherapy is used to treat recurrent HPC ( 5 ). (spandidos-publications.com)
  • Many studies showed that the carcinoem-bryonic antigen (CEA) and human cytokeratin fragment antigen 21-1 (CYFRA21-1) has a high value in predicting tumor recurrence and judging the prognosis of patients[ 2 , 3 ]. (ijpsonline.com)
  • The ability of circulating tumor DNA liquid biopsy assays to monitor cancer in situ also allows for the ability to monitor response to therapy, to detect minimal residual disease and as an early biomarker for cancer recurrence. (frontiersin.org)
  • The company's prodrugs are called Indukine molecules, and they are designed to unleash pro-inflammatory mechanisms on tumors while preventing unwanted side effects on nontarget tissue. (genengnews.com)
  • This may be due to late diagnosis of these tumors in our patients as most cases diagnosed at advanced stage and the sections were taken from deep tumor tissue to increase the number of tumor cells in our samples. (researchgate.net)
  • Methods: Flow cytometric analysis of DNA pliody and S-Phase Fraction (SPF) was done in 50 fresh tumor tissue sections of SGTs which diagnosed as 15 benign and 35 malignant tumors. (researchgate.net)
  • Nearly all multiple myeloma tumor cells express BCMA, while normal tissue expression is restricted to plasma cells and a subset of mature B cells. (bmj.com)
  • Efficacy was dependent on the number of CD8+ T cells able to recognize tumor antigens that infiltrated the malignant tissue. (unav.edu)
  • Assays on surgically removed tumor tissue are useful to determine indicators of treatment resistance, prognostication of outcome, or to molecularly characterize, classify, and determine the tissue of origin of a tumor. (frontiersin.org)
  • The ability to amplify RNA from microscopic amounts of tumor tissue extends the use of DC vaccination to virtually every cancer patient. (nova.edu)
  • Protein expression of the top prioritized antigen was immunohistochemically validated with a tissue microarray containing primary PTC (n = 741) and NTT (n = 108). (rug.nl)
  • Prostate-specific antigen (PSA), tissue inhibitor of metallopeptidase 1 (TIMP1) and tissue plasminogen activator (tPA), and their fucosylated glycoforms were captured by Aleuria Aurantia Lectin (AAL), followed by the multiplex magnetic bead-based immunoassay. (nih.gov)
  • T cells and TCR will be obtained from blood and tumor tissue and tested for neoantigen specificity and tumor reactivity. (unimedizin-mainz.de)
  • However, most GEP studies have typically been performed on whole tissue samples, containing varying degrees of tumor cell content, which results in uncertainties in data analysis. (lu.se)
  • Loading DCs ex vivo with tumor antigens can stimulate potent antitumor immunity in tumor-bearing mice. (nova.edu)
  • However, this finding has triggered further interest in utilising tumour-specific MHC-II to harness sustained anti-tumour immunity through the activation of CD4 + T helper cells. (portlandpress.com)
  • Thus, their reactivation represents an attractive way to unleash anti-tumour immunity. (portlandpress.com)
  • Indeed, the use of peptides for eliciting specific antitumor adaptive immunity is hindered by two main limitations: the efficient selection of the most optimal candidate peptides and the use of a highly immunogenic platform to combine with the peptides to induce effective tumor-specific adaptive immune responses. (elifesciences.org)
  • ABSTRACT To test the role of T helper cell Th1 immunity we recruited 24 patients with idiopathic thrombocytopenia associated with H. pylori seropositivity. (who.int)
  • The control group was patients initiating a tumor necrosis factor alfa (TNF-α) inhibitor. (bvsalud.org)
  • Tumor necrosis factor (TNF)-alpha inhibitors are used to treat a number of inflammatory conditions. (pharmacytimes.com)
  • Evidence exists that immune activation against hematopoietic elements frequently occurs in MDS patients, based on the identification of lymphocytic infiltrates in the marrow, oligoclonal expansion of T cells, and excessive production of tumor necrosis factor alpha. (acgtfoundation.org)
  • They are typically produced by tumor cells, but in some cases they may be produced by the body in response to malignancy or to certain benign conditions. (medscape.com)
  • In adults, CEA is primarily expressed in cells of tumors (some malignant, some benign) but they are particularly associated with the adenocarcinomas, such as those arising in the colon, lung, breast, stomach, or pancreas. (wikipedia.org)
  • Such treatments supposedly mediate their effects via the direct elimination of tumor cells. (nih.gov)
  • During chemotherapy or radiotherapy, DCs require signaling through TLR4 and its adaptor MyD88 for efficient processing and cross-presentation of antigen from dying tumor cells. (nih.gov)
  • Data demonstrated intrinsic targeting of patient-derived tumors by gamma delta T cells. (businesswire.com)
  • Some are focusing on small-molecule inhibitors for identifying and targeting key kinases that hamper T-cell responses to tumor cells. (genengnews.com)
  • The evaluation of the morphologic profile of the tumor cells is considered to be a determinant factor appropriating the aggressiveness of the tumor. (thejcdp.com)
  • In addition to this, morphologic profiles of the neoplastic cells are different and are unisomorphic at different zones in the same field as well as in different fields of the same tumor, thus creating a scope for confusion. (thejcdp.com)
  • It is believed that the most useful prognostic information can be obtained from the invasive front of a tumor, where the deepest and presumably the most aggressive cells reside. (thejcdp.com)
  • Hence, Ki-67 antigen-labeled cells can prove to be an effective tool to grade the tumors and finally contribute to the prognosis of the disease. (thejcdp.com)
  • To evaluate the anti-tumor activity of bb2121 in vivo , we employed a murine xenograft model in which 10 7 RPMI-8226 cells were subcutaneously implanted in NSG mice eighteen days prior to CAR T cell treatment, resulting in tumor volumes of 95 mm 3 at the time of infusion. (bmj.com)
  • In this setting, a single intravenous treatment of 5.2 x 10 6 bb2121 anti-BCMA CAR + T cells resulted in rapid tumor infiltration, followed by involution and complete tumor clearance after nineteen days. (bmj.com)
  • All mice treated with bb2121 anti-BCMA CAR T cells remained tumor free for the study duration (85 days). (bmj.com)
  • Autologous as well as allogeneic CD8 + T cells transduced with tumor antigen specific T cell receptors (TCR) may cause significant tumor lysis upon adoptive transfer. (oncotarget.com)
  • While all these entities are characterized by proliferation of highly atypical, anaplastic CD30+ T cells, the expression of T-cell specific antigens in the tumor cells is not consistently detectable. (uni-wuerzburg.de)
  • Bone marrow-derived dendritic cells (DCs) are the most potent antigen-presenting cells capable of activating naïve T cells. (nova.edu)
  • Consistent with these observations, preventative IGV-001 limited tumor progression and extended overall survival in mice intracranially challenged with GL261 cells, a benefit that was associated with an increase in tumor-specific T cells with effector features. (jefferson.edu)
  • The immune system plays a key role in surveillance against cancer, but some tumour cells evolve to escape immune elimination [ 4 ]. (biomedcentral.com)
  • A key mechanism of immune evasion deployed by tumour cells is to reduce neoantigen presentation through down-regulation of the antigen presentation machinery. (portlandpress.com)
  • Their expression in tumour cells is modulated by a complex interplay of genomic, transcriptomic and post translational factors involving multiple intracellular antigen processing pathways. (portlandpress.com)
  • Ongoing research investigates mechanisms invoked by cancer cells to abrogate MHC-I expression and attenuate anti-tumour CD8 + cytotoxic T cell response. (portlandpress.com)
  • The discovery of MHC-II on tumour cells has been less characterized. (portlandpress.com)
  • This review provides a comprehensive overview of physiologically conserved or novel mechanisms utilised by tumour cells to reduce MHC-I or MHC-II expression. (portlandpress.com)
  • Here we report that while exogenous administration of LPS was able to enhance adoptively transferred CD8 + T cells' tumor destruction, LPS treatment alone did not replace individual components of the tripartite ACT regimen, or obviate TBI. (biomedcentral.com)
  • In contrast, administering LPS after ACT potentiated the antitumor effectiveness of the regimen, thereby supporting the expansion of transferred tumor-specific CD8 + T cells over host CD4 + T cells. (biomedcentral.com)
  • Finally, TBI was no longer needed to regress tumors in mice who were depleted of host CD4 + T cells, given a tripartite ACT regimen and then treated with low dose LPS. (biomedcentral.com)
  • K562 cells express many of the antigens shown to be overexpressed in myeloid leukemias and MDS. (acgtfoundation.org)
  • ONTAK) to stage IV melanoma patients depleted CD4 + CD25 HI Foxp3 + regulatory T cells and expanded melanoma-specific CD8 + T cells. (biomedcentral.com)
  • However, high-avidity T cells specific for tumor-associated antigens (TAAs) are usually absent in patients because of self-tolerance. (unimedizin-mainz.de)
  • Focusing on advanced melanoma, we will investigate the antitumor activity of UniCAR NK cells in clinically relevant models. (unimedizin-mainz.de)
  • PeptiCRAd uses immunogenic viruses as active carriers of tumour-specific peptides to direct the immune system to specifically target and kill cancer cells. (helsinki.fi)
  • Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. (ucsf.edu)
  • This method is based on fusing protein antigens to an enzyme reporter, Renilla luciferase (Ruc), and expressing these fusions in mammalian cells, where mammalian-specific post-translational modifications can be added. (biomedcentral.com)
  • However, since such antigens do not carry post-translational modifications or may fold incorrectly, some immunoassays employ antigens produced in either yeast or insect cells. (biomedcentral.com)
  • Since mitochondria are responsible for providing energy for a cell, this leads to immune cells becoming exhausted by the time they enter the tumor bed, which leaves them unable to effectively fight off cancer cells. (umn.edu)
  • As a CRI CLIP Investigator, the Verma Lab seeks to change this by developing clinically relevant mitochondria-directed pharmacological treatment strategies that could be used to help immune cells last longer to make cell therapy more effective. (umn.edu)
  • The latter is a tool previously developed by Jacopo, 2020, able to identify tumor antigens similar to pathogen antigens in order to exploit molecular mimicry and tumor pathogen cross-reactive T cells in cancer vaccine development. (elifesciences.org)
  • GEP analyses were performed on highly purified, flow-cytometry sorted tumor-cells from eight subgroups of BCLs. (lu.se)
  • This enabled identification of TFs that can be uniquely associated to the tumor cells of chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), hairy cell leukemia (HCL), and mantle cell lymphoma (MCL). (lu.se)
  • Prostate-specific antigen (PSA) is a protein produced by normal prostate cells. (medscape.com)
  • The malignant tumours consisted of 18 adenoid cystic adenomas, 10 mucoepidermoid carcinomas, 5 acinic cell carcinomas, 5 carcinoma in pleomorphic adenoma as well as of 12 other malignancies belonging to 7 different tumour entities. (researchgate.net)
  • Background: Wilms tumor (WT) is one of the most common malignancies in childhood. (uni-wuerzburg.de)
  • We have developed a genetically modified tumor cell vaccine for the treatment of myeloid malignancies. (acgtfoundation.org)
  • Patients who have AN associated with malignancies also have skin changes involving the scalp, areolae, and eyelids. (medscape.com)
  • Antibodies blocking the immune checkpoint cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-1-ligand 1 (PD-L1) antigens have been tested in several gastrointestinal malignancies. (medscape.com)
  • Serum from individuals with colorectal carcinoma often has higher levels of CEA than healthy individuals (above approximately 2.5 µg/L). CEA measurement is mainly used as a tumor marker to monitor colorectal carcinoma treatment, to identify recurrences after surgical resection, for staging or to localize cancer spread through measurement of biological fluids. (wikipedia.org)
  • While no expression correlates of age, serum prostate specific antigen (PSA), and measures of local invasion were found, a set of genes was identified that strongly correlated with the state of tumor differentiation as measured by Gleason score. (nih.gov)
  • The levels of serum tumor markers were detected by electrochemiluminescence immunoassay. (ijpsonline.com)
  • This study aimed at optimizing molar doses and pretargeting interval of TF2 and 68 Ga-labeled IMP288 for immuno-PET in relapsed MTC patients with calcitonin serum levels greater than 150 pg/mL. (snmjournals.org)
  • After initial surgery, serum calcitonin is still detectable in nearly 20% of patients, suggesting residual disease, and imaging including neck ultrasonography, neck and chest CT, liver contrast-enhanced CT or MRI, and spine and pelvic bone MRI is recommended when serum calcitonin is higher than 150 pg/mL ( 1 , 2 ). (snmjournals.org)
  • Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. (nih.gov)
  • Tests employing bacterial-produced proteins can produce high backgrounds because it is difficult to completely eliminate or block serum antibodies reactive with trace amounts of bacterial contaminants present in most antigen preparations, even in pharmaceutical grade preparations [ 3 ]. (biomedcentral.com)
  • Elevated CEA levels should return to normal after successful surgical removal of the tumor and can be used in follow up, especially of colorectal cancers. (wikipedia.org)
  • For patients with these advanced cancers, the prognosis remains poor and patients are in need of new, more effective and better tolerated therapies," said Chen Schor, President and Chief Executive Officer at Adicet Bio. (businesswire.com)
  • Prostate tumors are among the most heterogeneous of cancers, both histologically and clinically. (nih.gov)
  • Cell kinetic data may also be a useful adjunct to histologically based tumor classifications, and are among the most important indicators of treatment response and relapse in many types of cancers. (thejcdp.com)
  • The Ki-67 antigen is one such reliable biomarker of cancers, which is now being widely studied to reveal the prognostic indication of the disease. (thejcdp.com)
  • For many there are better options with an ever-expanding array of drugs, including estrogen blockers and drugs that destroy cancers by attacking specific proteins on the surface of tumors. (wanttoknow.info)
  • With the advancements in prostate-specific antigen (PSA) screening, most prostate cancers are detected at the regional stages (clinically localised disease). (biomedcentral.com)
  • Recent reports have also described a relatively early onset of breast and prostate cancers in patients with immunodeficiency [ 12 , 13 ]. (biomedcentral.com)
  • David J. Grignon In spite of the slow progression rates common to most prostate cancers , it is well recognized that a subset of patients will experience a more aggressive course with many losing their lives to this malignancy. (karger.com)
  • It is safe to say that in these countries the majority of prostate cancers are now being clinically diagnosed while still localized, and many organ-confined tumors. (karger.com)
  • PRIMARY OBJECTIVE: I. Evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers. (mycancergenome.org)
  • Clinically, it is still challenging to differentiate aggressive from non-aggressive prostate cancers (Pca) by non-invasive approaches. (nih.gov)
  • Overdiagnosis, which occurs when screening procedures detect cancers that would never become clinically apparent in the absence of screening. (cancer.gov)
  • In general, overdiagnosis is more common in older individuals and those with otherwise limited life expectancy since the slowly growing lesions associated with overdiagnosed cancers have less time to become clinically apparent in such persons. (cancer.gov)
  • We have characterized this technology with sera from patients having three different types of cancers. (biomedcentral.com)
  • The risk of not treating patients with aggressive cancers early enough, the long-term effects and the impact on quality of life are unknown. (cancercentrum.se)
  • The scientific hypothesis is that this alternative schedule for follow-up will identify the aggressive cancers earlier with less health-care resources and better quality of life for the patients, without increasing the total proportion of patients receiving radical therapy within 5 years. (cancercentrum.se)
  • A typical Indukine consists of a wild-type cytokine, an inactivation domain to block activity in the periphery, a tumor-protease-sensitive linker that activates in the tumor microenvironment, and a half-life extension domain. (genengnews.com)
  • While inflammatory injury drives both fibrogenesis and carcinogenesis, the tolerogenic microenvironment of the liver conveys immunosuppressive effects that encourage tumor growth. (mdpi.com)
  • MHC-I and MHC-II proteins are key components of the antigen presentation machinery responsible for neoantigen presentation to CD8 + and CD4 + T lymphocytes, respectively. (portlandpress.com)
  • RÉSUMÉ Afin de tester le rôle de l'immunité des lymphocytes T auxiliaires de type Th1, nous avons recruté 24 patients atteints de thrombocytopénie idiopathique associée à une séropositivité pour Helicobacter pylori. (who.int)
  • Suggestive evidence of clinically related responses was seen in both the trials. (nova.edu)
  • Latent tuberculosis infection (LTBI) is a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). (pharmacytimes.com)
  • Therefore to overcome the biological limitations and technical problems associated with bacterially and non-mammalian-produced antigens, we have developed a simple immunoassay that combines conventional immunoprecipitation techniques with a novel approach for the production of tumor antigens. (biomedcentral.com)
  • Many new tumor markers have been discovered since the development of monoclonal antibodies, and most tumor markers are now detected with them. (medscape.com)
  • Monoclonal antibodies directed toward nuclear antigens are increasingly used as tools to obtain valuable information concerning the proliferative changes of the tumors. (thejcdp.com)
  • Recombinant targeting modules will be based on antibodies and soluble single-chain fragments of TCR specific for melanoma antigens. (unimedizin-mainz.de)
  • Assays detecting human antigen-specific antibodies are medically useful. (biomedcentral.com)
  • However, the usefulness of existing simple immunoassay formats is limited by technical considerations such as sera antibodies to contaminants in insufficiently pure antigen, a problem likely exacerbated when antigen panels are screened to obtain clinically useful data. (biomedcentral.com)
  • We show that 20-85% of these sera contain significant titers of antibodies against at least one of five frequently mutated and/or overexpressed tumor-associated proteins. (biomedcentral.com)
  • Anti-PD-1 or PD-L1 antibodies alone or in combination with CTLA-4 were shown to induce objective responses in approximately 10% to 20% of patients with gastric and gastroesophageal adenocarcinoma in small nonrandomized trials. (medscape.com)
  • TACE combined with lenvatinib and sintilimab in the treatment of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma can effectively control the tumor progression and prolong the survival time of patients. (hindawi.com)
  • However, TACE can induce hypoxia and increase the level of VEGF in HCC, which may be the driving factor of tumor growth, progression, and metastasis [ 4 , 5 ]. (hindawi.com)
  • To explore the application value of tumor markers carcinoembryonic antigen and cytokeratin 19 fragment in the progression and prognosis of middle-advanced non-small cell lung cancer. (ijpsonline.com)
  • In the recently presented study, KEYNOTE-059, [ 9 ] 259 patients with advanced refractory gastric cancer received pembrolizumab 200 mg every three weeks until progression. (medscape.com)
  • The knowledge of cell proliferative activity and its cellular proteins, which are involved in the control of cell proliferation, are essential components for understanding the biology of tumors. (thejcdp.com)
  • Adavosertib, everolimus, and trametinib are drugs that each target a specific variation in tumors by blocking different proteins needed for cell growth. (mycancergenome.org)
  • 1. Examine the in vivo effect of: a) DNA methyltransferase inhibitors, b) HDACi, and c) IMiDs on the response to GM-CSF tumor vaccines in a mouse model (year 1). (acgtfoundation.org)
  • The in-vivo data demonstrated a synergistic improvement in tumour clearance when checkpoint inhibitors were combined with Valo Tx's platform. (helsinki.fi)
  • Mean length of follow-up was 41.5 months and 67% patients had Gleason scores 5-7. (prostatecalculator.org)
  • The level of fucosylated glycoproteins was correlated with patients' Gleason score of the tumor. (nih.gov)
  • By exploiting the most advanced technologies (nanoparticle-based vaccines, neo-antigens identification and validation, etc.), suitable preclinical models, and investigation of anti-tumour immune responses in cancer patients, we are developing innovative strategies potentially able to improve current approaches. (edu.au)
  • There was a rat model, and the target antigen was known in the rat. (medscape.com)
  • Before 2009, we didn't know what the major target antigen in adult MN was. (medscape.com)
  • Positive immunoreactivity indicated the presence of brown precipitate in the nucleus at the site of the target antigen. (thejcdp.com)
  • Results: 93.3% of the benign SGTs tumors were diploid, while only 34% of malignant tumors were diploid and 66% were aneuploid. (researchgate.net)
  • Non-Small Cell Lung Cancer (NSCLC) was one of the most common malignant tumors in the clinic, with high morbidity and mortality, accounting for about 80 % of the total number of lung cancer in China. (ijpsonline.com)
  • and 2) whether addition of i.v. CDX-1127 (Varlilumab) increases the response rate and magnitude of CD4+ and CD8+ T-cell responses against the IMA950 peptides in post-vaccine peripheral blood mononuclear cell (PBMC) samples obtained from participating patients. (ucsf.edu)
  • These peptides were then tested in our previously described oncolytic cancer vaccine platform PeptiCRAd, a vaccine platform that combines an immunogenic oncolytic adenovirus (OAd) coated with tumor antigen peptides. (elifesciences.org)
  • On the preclinical front, we are prioritizing the development of ADI-270 as our lead preclinical candidate in renal cell carcinoma and other solid tumor indications. (businesswire.com)
  • Adicet has reprioritized its preclinical pipeline to focus on the development of ADI-270 as its lead preclinical candidate for renal cell carcinoma, with potential in other solid tumor indications. (businesswire.com)
  • CEA is elevated more in tumors with lymph node and distant metastasis than in organ-confined tumors and, thus, varies directly with tumor stage. (wikipedia.org)
  • In our series 64% of patients had organ-confined cancer, 33% positive margin and 14% had seminal vesicle invasion. (prostatecalculator.org)
  • The malignant SGTs had higher SPF than the benign tumors but with no significant difference. (researchgate.net)
  • Because pathologic diagnosis of ovarian cancer is difficult without laparotomy, tumor markers such as CA-125, in addition to diagnostic imaging, are useful in preoperative evaluation for ovarian cancer. (medscape.com)
  • The incidence of NSCLC was relatively hidden, the early symptoms were not obvious, the diagnosis of patients was often in the middle-advanced stage. (ijpsonline.com)
  • of detection with transrectal ultrasound and prostate-specific antigen(PSA) have resulted in a dramatic shift in the stage of disease at diagnosis. (karger.com)
  • Etanercept was discontinued, and the patient was referred to an infectious disease specialist, who made a diagnosis of acquired LTBI due to TNF-alpha inhibitor therapy with etanercept. (pharmacytimes.com)
  • The appearance of paraneoplastic AN usually coincides with the presence of malignancy, but it can precede or follow the diagnosis of cancer and thus may signal a relapse in patients with a history of cancer. (medscape.com)
  • Once the diagnosis, palliative care are applicable in the course of the illness until death and are performed according to a draft of continuing care that emphasizes listening, communication, establishing confidence with the patient and his family [3]. (symbiosisonlinepublishing.com)
  • But there are many other such studies that we preform clinically to guide disease diagnosis and monitoring response to therapy. (hopkinsmedicine.org)
  • Thus, H. pylori infection should be considered in the differential diagnosis of all cases of thrombocytopenia, and should be eradicated in all H. pylori-positive patients with thrombocytopenia. (who.int)
  • Early diagnosis and effective treatment of TB among HIV-infected patients are critical for curing TB, minimizing the negative effects of TB on the course of HIV, and interrupting the transmission of Mycobacterium tuberculosis to other persons in the community. (cdc.gov)
  • Socioeconomic status, access to care, risk factor patterns, and stage at diagnosis for head and neck cancer among black and white patients. (who.int)
  • In vitro testing of primary tumor cultures provided clear evidence of a potential utility of retinoids in Wilms tumor treatment based on the analysis of gene expression, proliferation, differentiation and apoptosis. (uni-wuerzburg.de)
  • Objectives: The P-30 protein (P30), a novel RNase, in combination with tamoxifen (TAM) has anti-tumor activity in vitro and in patients with pancreatic cancer. (uky.edu)
  • Immunohistochemical examination revealed positive expression of cluster of differentiation 34(CD34), vimentin and CD99, and negative expression of epithelial membrane antigen, S100 and glial fibrillary acidic protein. (spandidos-publications.com)
  • Conclusions These results support treatment with IGV-001 to induce clinically relevant ICD-driven anticancer immune responses in patients with GBM. (jefferson.edu)
  • After DAB/IL2 administration, 16.7% of the 60 patients had partial responses, 5% stable disease and 15% mixed responses. (biomedcentral.com)
  • Importantly, 45.5% of the chemo/immuno-naïve sub-population (11/60 patients) experienced partial responses. (biomedcentral.com)
  • Project aiming at characterizing the role of neo-antigen immune responses in mouse and human breast cancer. (edu.au)
  • Project aiming at characterising tumour neo-antigen-specific immune responses in oesophageal adenocarcinoma patients with long-term survival. (edu.au)
  • In a phase II study of pembrolizumab in patients with microsatellite-high (MSI-H) solid tumors, the objective response rate was 39.6% (95% CI = 31.7% to 47.9%), including 7.4% complete responses (CRs) and 32.2% partial responses (PRs). (medscape.com)
  • 4 The Centers for Disease Control and Prevention (CDC) recommends systematic testing and treatment of LTBI in patients initiating the use of TNF-alpha inhibitors. (pharmacytimes.com)
  • 10 This case demonstrates the importance of screening for LTBI in patients receiving TNF-alpha inhibitors. (pharmacytimes.com)
  • Tumors from these patients will be used for peptide ligandome analyses, predictive in-situ biomarker analysis by immunohistochemistry, MALDI-TOF imaging mass spectrometry and RNA sequencing (RNAseq). (unimedizin-mainz.de)
  • We have developed a model for calculating such risk, which accounts for various tumor characteristics. (prostatecalculator.org)
  • Total DNA level in swabs was measured tifi ed human virus initially discovered in tumor tis- by using the LightCycler Control DNA Kit (Roche Diag- sues of patients with Merkel cell carcinoma (MCC), a rare nostics, Meylan, France), and results were expressed as but aggressive skin cancer ( 1 ). (cdc.gov)
  • Intracranial hemangiopericytoma (HPC) is a rare tumor well-known for clinically aggressive behavior in growth and infiltration. (spandidos-publications.com)
  • With current therapy protocols up to 90% of patients can be cured, but there is still a need to improve therapy for patients with aggressive WT and to reduce treatment intensity where possible. (uni-wuerzburg.de)
  • In this study, we have investigated levels of glycoproteins and their fucosylated glycoforms in sera of Pca patients, as well as the potential utility of fucosylated glycoproteins in the identification of aggressive Pca. (nih.gov)
  • The ratio of fucosylated PSA showed a marked increase in aggressive tumors in comparison to non-aggressive tumors. (nih.gov)
  • Our data demonstrated that fucosylated PSA has a better predictive power to differentiate aggressive tumors from non-aggressive tumors, than that of native PSA and two other glycoproteins. (nih.gov)
  • swabs from patients with MCC, in 58 (74.3 %) of 78 from Most studies of MCPyV DNA detection in skin sam- patients with other cutaneous diseases, and in 56 (80.0%) ples have been performed on biopsy samples. (cdc.gov)
  • A total of 5922 H&E sections representing 7473 biopsy cores from 423 patient cases (digitized using three scanners) were assessed concerning tumor detection. (cdc.gov)
  • Development and validation of clinically applicable protocols for the identification of tumour-specific immunogenic neo-epitopes to be exploited in personalised vaccination approaches. (edu.au)
  • 21 day cycles) was administered to 60 unresectable stage IV melanoma patients and response rates were assessed using a combination of 2-[ 18 F]-fluoro-2-deoxy-glucose (FDG)-positron emission tomography (PET) and computed tomography (CT) imaging. (biomedcentral.com)
  • Unfortunately, none of these immunological strategies have improved the median overall survival of newly diagnosed stage IV melanoma patients beyond 1 year. (biomedcentral.com)
  • ICI therapy options such as anti-PD1 are promising treatment strategies for patients with advanced stages of melanoma-but even in best-case scenarios, approximately only half of patients respond to treatment. (umn.edu)
  • The treatment of patients in this stage is more complex than that in the early stage, and their prognosis is better than that in the advanced stage, so special attention should be paid to it. (hindawi.com)
  • In their various recent seminal studies, Bryne 3 suggested that the invasive front of the tumor is the region which enunciates the cell character and thus, could contribute toward prognosis. (thejcdp.com)
  • EBV-positive tumors have a higher frequency of Crohn's disease-like lymphoid reaction that correlates with an improved prognosis in patients with gastric cancer. (medscape.com)
  • Sometimes, tumor marker values may rise after effective treatment (due to cell lysis), but the increase may not portend treatment failure. (medscape.com)
  • His Swim Across America project aims to use RealSeqS to develop novel molecular diagnostics to reliably classify bile duct strictures, leading to correct treatment options for cholangiocarcinoma and pancreatic ductal carcinoma patients. (swimacrossamerica.org)
  • At present, both the European Association for the Study of the Liver (EASL) [ 2 ] and the American Association for the Study of Liver Diseases (AASLD) [ 3 ] recommend transarterial chemoembolization (TACE) as the standard treatment option for patients with intermediate-stage (BCLC stage B) HCC. (hindawi.com)
  • said he knew of no other study in which a treatment completely obliterated a cancer in every patient. (wanttoknow.info)
  • These data demonstrate the effectiveness of our lentivirus-based CAR T cell manufacturing process and support the further development of bb2121 for the treatment of patients with multiple myeloma. (bmj.com)
  • Clinically, the comprehensive treatment regimen based on chemotherapy was mainly adopted. (ijpsonline.com)
  • Genes deregulated in high risk tumors showed opposite changes upon treatment suggesting a positive effect of retinoids. (uni-wuerzburg.de)
  • We show that treatment of the mice with a combination of anti-CTLA-4 + anti-PD1 mAbs results in partial clearance of the tumor with an improvement in survival. (unav.edu)
  • Therefore, understanding the pathological mechanisms and identification of potent prognostic biomarkers for BCR are needed to identify patients at high-risk of disease development and guide treatment decisions. (biomedcentral.com)
  • According to the CDC, the treatment must be modified if the patient was in contact with drugresistant TB and a consultation with a TB expert is suggested. (pharmacytimes.com)
  • This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). (mycancergenome.org)
  • It is not yet known whether testing patients for variations in their tumor and assigning treatment targeting the variation is more effective than standard non-targeted therapy in treating advanced solid tumors. (mycancergenome.org)
  • OUTLINE: Patients are assigned to 1 of 4 treatment regimens corresponding to one of their mutation/amplification categories. (mycancergenome.org)
  • No longer an active study drug as of March 2018) After completion of study treatment , patients are followed up for 30 days. (mycancergenome.org)
  • To address this need, we will link an ImmuNEO module to the DKTK MASTER program that will include exome and transcriptome-sequenced patients on a pan-cancer basis who receive treatment with checkpoint modulators. (unimedizin-mainz.de)
  • Palliative care is an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual [2]. (symbiosisonlinepublishing.com)
  • Diagnostic tests are the support of a strong health care system, they play a decisive role in making decision and help to direct patients to appropriate care, modifying their treatment and accompany them with general or specialist supportive care [5]. (symbiosisonlinepublishing.com)
  • PET imaging is also used to follow the progress of patients undergoing treatment. (hopkinsmedicine.org)
  • [ 10 ] Based partly on this study, pembrolizumab was recently approved by the FDA for treatment of advanced MSI-H tumors. (medscape.com)
  • All HIV-infected patients undergoing treatment for TB should be evaluated for antiretroviral therapy, because most patients with HIV-related TB are candidates for concurrent administration of antituberculosis and antiretroviral drug therapies. (cdc.gov)
  • Ideally, the management of TB among HIV-infected patients taking antiretroviral drugs requires a) directly observed therapy, b) availability of experienced and coordinated TB/HIV care givers, and in most situations, c) use of a TB treatment regimen that includes rifabutin instead of rifampin. (cdc.gov)
  • Because alternatives to the use of rifampin for antituberculosis treatment are now available, the previously recommended practice of stopping protease inhibitor therapy to allow the use of rifampin for TB treatment is no longer recommended for patients with HIV-related TB. (cdc.gov)
  • Physicians and patients also should be aware that paradoxical reactions might occur during the course of TB treatment when antiretroviral therapy restores immune function. (cdc.gov)
  • treatment can restore immune function in most patients if suppression of replication is sustained. (msdmanuals.com)
  • In the SAMS (SAMS-FU and SAMS-ObsQoL) the quality of life and pelvic symptoms of patients on active surveillance will be investigated and compared to those of patients receiving immediate treatment with curative intent. (cancercentrum.se)
  • Conclusion: DNA aneuploidy may be a key indicator for tumors activity and malignancy in SGTs, while the SPF has a minor role in the evaluation of SGTs activity. (researchgate.net)
  • Whichever date is selected, the date of only: date of first consultation at the out- incidence should not be later than the date of patient clinic because of this malignancy. (who.int)
  • available other than the fact that the patient has died because of a malignancy. (who.int)
  • Beta-hCG and alpha-fetoprotein have proved to be useful markers for ovarian germ cell tumors. (medscape.com)
  • These results delineate a clinically relevant immunoadjuvant pathway triggered by tumor cell death. (nih.gov)
  • Some localized melanomas may result from azathioprine, which acts synergistically with ultraviolet radiation, while T-cell depleting induction therapies may promote late stage tumors. (cdc.gov)
  • B cell maturation antigen (BCMA) is an attractive CAR T cell target to treat patients with multiple myeloma. (bmj.com)
  • Background CD30+ T-cell lymphoproliferations comprise a spectrum of clinically heterogeneous entities, including systemic anaplastic large cell lymphomas (ALK- and ALK+) and primary cutaneous CD30+ T-cell lymphoproliferative disorders. (uni-wuerzburg.de)
  • Design and Methods We evaluated biopsies from 19 patients with primary cutaneous CD30+ lymphoproliferative disorders, 38 with ALK- and 33 with ALK+ systemic anaplastic large cell lymphoma. (uni-wuerzburg.de)
  • Combining tumor-specific adoptive T cell therapy to the aCTLA-4/aPD1/rIL2 or aCTLA-4/aPD1/aCD137 reg-imens enhances efficacy in a synergistic manner. (unav.edu)
  • Whether this represents a secondary event in response to cell injury and the generation of neo-antigens, or an initiating event inducing immunopathology, remains controversial. (acgtfoundation.org)
  • The tumor antigens are fused to an enzymatic reporter, Ruc, and produced in mammalian cell cultures, where mammalian-specific post-translational modifications can be added. (biomedcentral.com)
  • 8000 peptide targets from the CT26 tumor cell line. (elifesciences.org)
  • This immunopeptidomics-based pipeline was carefully validated in a murine colon tumor model CT26. (elifesciences.org)
  • According to the Barcelona Clinic Liver Cancer (BCLC) staging standard, HCC is divided into four stages, of which stage B is equivalent to the intermediate stage of Tumor Node Metastasis (TNM) staging. (hindawi.com)
  • In contrast, bortezomib (a current standard of care for multiple myeloma) merely suppressed tumor growth during administration and tumors progressed in all mice by day fifty (n = 10). (bmj.com)
  • Mice were followed for the growth of subsequently implanted or pre-existing tumors and survival. (jefferson.edu)
  • Moreover, we found that sequentially administering LPS during or one day prior to ACT therapy compromised tumor regression. (biomedcentral.com)
  • Aneuploid tumors produce more CEA than diploid tumors. (wikipedia.org)
  • She will also develop a user-friendly, publicly-available graphical user interface (GUI) for bioinformatic identification of antigen-specific TCRs. (swimacrossamerica.org)
  • While the biospecimens used in this study are from lung cancer patients, if successful, this assay will have broad applicability to all tumor types for which antigen-specific TCRs can be studied. (swimacrossamerica.org)
  • Methods: Review of data from several historical and contemporary series of patients undergoing radical prostatectomy. (karger.com)
  • Nevertheless, MDS are thought to be immunologically responsive diseases, as immunomodulatory drugs can induce remissions, and allogeneic bone marrow transplantation can be curative in the small fraction of patients for whom this is an option. (acgtfoundation.org)
  • 1] This article focuses on cutaneous paraneoplastic syndromes caused by solid tumors. (medscape.com)
  • Details of Adicet's lead optimization process and differentiated prostate specific membrane antigen (PSMA) binding moiety were presented at the conference. (businesswire.com)
  • The company asserts that its Indukines can enhance tumor-specific killing while minimizing undesirable off-target effects. (genengnews.com)
  • METHODS: We used a data-driven prioritization strategy based on transcriptomic profiles of 97 primary PTCs and 80 normal thyroid tissues (NTT) to identify tumor-specific antigens for a clinically available near-infrared fluorescent tracer. (rug.nl)
  • This study aimed to determine if molecular fluorescence-guided imaging (MFGI) and spectroscopy can be useful for detecting PTC nodal metastases (NM) and to identify negative central compartments intraoperatively.METHODS: We used a data-driven prioritization strategy based on transcriptomic profiles of 97 primary PTCs and 80 normal thyroid tissues (NTT) to identify tumor-specific antigens for a clinically available near-infrared fluorescent tracer. (rug.nl)
  • This technology has several advantages over current quantitative immunoassays including its relative simplicity, its avoidance of problems associated with E. coli -produced antigens and its use of antigens that can carry mammalian or disease-specific post-translational modifications. (biomedcentral.com)
  • While these antigens may fold correctly and carry post-translational modifications, they will not carry either mammalian- or disease-specific posttranslational modifications. (biomedcentral.com)
  • Our final goal is to provide effective treatments for cancer patients with reduced non-specific side-effects. (edu.au)
  • To include biochemical and/or immunological markers which are specific for a tumour site (Table 2). (who.int)
  • The timing of LPS administration and the requirement of individual components of the tripartite therapy were evaluated based on tumor growth and the phenotype of recovered splenocytes by flow cytometry. (biomedcentral.com)